HRP20170610T1 - Pedijatrijske otopine koje sadrže propranolol - Google Patents

Pedijatrijske otopine koje sadrže propranolol Download PDF

Info

Publication number
HRP20170610T1
HRP20170610T1 HRP20170610TT HRP20170610T HRP20170610T1 HR P20170610 T1 HRP20170610 T1 HR P20170610T1 HR P20170610T T HRP20170610T T HR P20170610TT HR P20170610 T HRP20170610 T HR P20170610T HR P20170610 T1 HRP20170610 T1 HR P20170610T1
Authority
HR
Croatia
Prior art keywords
vol
solution according
amount
propranolol
saccharin
Prior art date
Application number
HRP20170610TT
Other languages
English (en)
Inventor
Christine Chaumont
Jean-François CORDOLIANI
Elie Leverd
Valérie MUGUET
Original Assignee
Pierre Fabre Dermatologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40940328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20170610(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pierre Fabre Dermatologie filed Critical Pierre Fabre Dermatologie
Publication of HRP20170610T1 publication Critical patent/HRP20170610T1/hr
Publication of HRP20170610T4 publication Critical patent/HRP20170610T4/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Seasonings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (14)

1. Vodeno-bezalkoholna pedijatrijska otopina koja sadrži propranolol ili njegove farmaceutski prihvatljive soli, zaslađivač koji nije tipa šećera i manje od 0.0 tež-% / vol% konzervansa, osim samog propranolola, za uporabu lijeka u liječenju hemangioma.
2. Otopina sukladno patentnom zahtjevu 1, za uporabu kao lijek u liječenju kapilarnih hemangioma.
3. Otopina sukladno patentnom zahtjevu 1, za uporabu kao lijek u liječenju kapilarnih dječjih hemangioma.
4. Otopina suklano bilo kojem patentnih zahtjevu od 1 do 3, pri čemu je propranolol ili njegove farmaceutski prihvatljive soli u količini od 0.01 do 5% tež/vol, primjerice 0.01 do 1% tež/vol.
5. Otopina sukladno bilo kojem od patentnih zahtjeva 1 do 4, koji dalje sadrži najmanje jedan aromat i/ili najmanje jedno sredstvo za povećanje viskoznosti.
6. Otopina prema patentnom zahtjevu 5, pri čemu je najmanje jedno sredstvo za poboljšanje okusa odabrano od bilo koje od aroma trešnje, limuna, limete, mandarine, narnače, mandarine, metvice, jagode, banane, karamele, sladića, krunica, breskve, maline, slatkiš od ražličitog voća, grejp, vanilije, vrhnje, čokolade, okus grožđa ili njihova smjesa, na primjer odabran od arome vanilije i jagode, i prisutan je u iznosu od 0 do 5% tež/vol, npr. od 0.01 do 1% tež/vol i npr. od 0.01 do 0.5 % tež/vol.
7. Otopina prema patentnom zahtjevu 6, naznačen time da je najmanje jedno sredstvo za poboljšanje okusa od vanilije u količini od 0.01 do 0.5% tež/vol.
8. Otopina prema bilo kojem od patentnih zahtjeva 5 do 7, pri čemu je najmanje jedno sredstvo za povećanje viskoznosti odabrano od derivata celuloze, hidroksietilceluloze, hidroksipropilceluloze, hidroksipropilmetilceluloze, ili metilceluloze, poloksamera, od guma, guar gume, tragantove gume, gume akacije, ksantan gume, gelan gume, alginskih derivata, alginske kiseline, natrijum alginata, polivinilpirolidona, od silikata, bentonita, laponita, veegum, specifičnije od ne-ionskih poloksamera, polivinilpirolidona i celulozni eteri, u količini od 0 do 15% tež/vol, npr. od 0.1 do 10% tež/vol, npr. od 0.1 do 5 % tež/vol i npr. od 0.1 do 0.5% tež/vol.
9. Optopina sukladno patentnom zahtjevu 8 pri čemu je najmanje jedno sredstvo za povećanje viskoznosti hidroksietilceluloza.
10. Otopina sukladno bilo kojem od patentnih zahtjeva 1 do 9, koji dalje sadrži sredstvo za reguliranje pH ili pufer, i pri tome se pH nalazi između 2 i 6, primjerice 2 i 5.5, primjerice između 3.0 i 5.0, npr. 2.0 i 5.0, npr. 2.5 i 4.
11. Otopina sukladno bilo kojem od patentnih zahtjeva 1 do 10, pri čemu je najmanje jedan zaslađivač tipa ne-šećer saharina, soli saharina, natrij saharin, kalcij saharin, sukraloze, kalij acesulfam, steviosida, steviol, manitol, eritritol, laktitola, maltitol, alitam, mirakulin, monelin, taumatin, i njihova smjesa, i primjerice odabran od saharin natrija u količini od 0.05 do 0.5% tež/vol.
12. Otopina sukladno patentnom zahtjevu 6 pri čemu je propranolol prisutan u količini od 0.250 do 1% tež/vol i vanilija je prisutna u količini od 0.01 do 1% tež/vol i pri tome spomenuti vodena otopina ne sadrži konzervans.
13. Otopina sukladno bilo kojem od patentnih zahtjeva 1 do 12, pri čemu propranolol ili njegove farmaceutski prihvatljive soli su propranolol hidroklorid u količini od 0.428 ili 0.57 % tež/vol pri čemu je najmanje jedno sladilo natrijev saharin u količini od 0.15% tež/vol, pri čemu je najmanje jedan agens za poboljšanje okusa smjesa vanilije i jagode u količini od 0.32% tež/vol i najmanje jedno sredstvo za povećanje viskoznosti je hidroksietilceluloza u količini od 0.35 % tež/zapr.
14. Otopina sukladno bilo kojem od patentnih zahtjeva 1 do 13, pri čemu je otopina je otopina za višenamjensku uporabu.
HRP20170610TT 2009-04-21 2010-04-12 Pedijatrijske otopine koje sadrže propranolol HRP20170610T4 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09290298A EP2246044A1 (en) 2009-04-21 2009-04-21 Paediatric solutions comprising a beta-blocker
EP10717263.7A EP2421504B2 (en) 2009-04-21 2010-04-12 Paediatric solutions comprising propranolol
PCT/IB2010/051573 WO2010122442A1 (en) 2009-04-21 2010-04-12 Paediatric solutions comprising a beta-blocker

Publications (2)

Publication Number Publication Date
HRP20170610T1 true HRP20170610T1 (hr) 2017-07-28
HRP20170610T4 HRP20170610T4 (hr) 2022-12-09

Family

ID=40940328

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20170610TT HRP20170610T4 (hr) 2009-04-21 2010-04-12 Pedijatrijske otopine koje sadrže propranolol
HRP20181408TT HRP20181408T4 (hr) 2009-04-21 2018-09-03 Pedijatrijska otopina koja sadrži beta-blokator

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20181408TT HRP20181408T4 (hr) 2009-04-21 2018-09-03 Pedijatrijska otopina koja sadrži beta-blokator

Country Status (32)

Country Link
US (2) US20120035270A1 (hr)
EP (4) EP2246044A1 (hr)
JP (1) JP5695029B2 (hr)
KR (1) KR101713866B1 (hr)
CN (1) CN102405041A (hr)
AR (2) AR076338A1 (hr)
AU (1) AU2010240551B2 (hr)
BR (1) BRPI1015447B1 (hr)
CA (1) CA2755175C (hr)
CL (1) CL2011002634A1 (hr)
CO (1) CO6410278A2 (hr)
CY (2) CY1119390T1 (hr)
DK (2) DK2421504T4 (hr)
ES (2) ES2685178T5 (hr)
GE (1) GEP20146087B (hr)
HR (2) HRP20170610T4 (hr)
HU (2) HUE039937T2 (hr)
IL (1) IL214674A (hr)
LT (2) LT2421504T (hr)
MA (1) MA33003B1 (hr)
MX (1) MX337463B (hr)
NZ (1) NZ594592A (hr)
PL (2) PL2497461T5 (hr)
PT (2) PT2497461T (hr)
RS (2) RS57668B2 (hr)
RU (1) RU2011139233A (hr)
SG (1) SG172960A1 (hr)
SI (2) SI2497461T2 (hr)
TN (1) TN2011000350A1 (hr)
TW (1) TWI429459B (hr)
UA (1) UA107570C2 (hr)
WO (1) WO2010122442A1 (hr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246044A1 (en) 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
SI3287123T1 (sl) 2011-03-04 2020-07-31 Gruenenthal Gmbh Vodna farmacevtska formulacija tapentadola za peroralno uporabo
JP2019142972A (ja) * 2011-03-04 2019-08-29 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
SI2680833T1 (sl) * 2011-03-04 2016-06-30 Gruenenthal Gmbh Parenteralno dajanje tapentadola
US9724297B2 (en) * 2014-04-01 2017-08-08 Arbor Pharmaceuticals, Inc. Sotalol compositions and uses of the same
MX2017012312A (es) 2015-03-27 2018-01-18 Gruenenthal Gmbh Formulacion estable para administracion parenteral de tapentadol.
BR112019005439A2 (pt) 2016-09-23 2019-06-18 Gruenenthal Gmbh formulação estável para administração parenteral de tapentadol
CN108261411B (zh) * 2016-12-30 2021-04-30 武汉科福新药有限责任公司 用于婴幼儿血管瘤治疗的口腔膜剂及其制备方法
CN107320467A (zh) * 2017-07-21 2017-11-07 江苏云阳集团药业有限公司 一种盐酸普萘洛尔药用组合物及其制备方法
CN108299279B (zh) * 2018-02-09 2021-03-23 北京梅尔森医药技术开发有限公司 取代芳基胺醇化合物及其制备方法和用途
US11547123B2 (en) * 2019-08-16 2023-01-10 The Folger Coffee Company Methods for reducing negative flavor attributes in coffee and compositions therefrom
EP4223283A1 (en) 2020-09-30 2023-08-09 Nissan Chemical Corporation Water-soluble complex containing beta- blocker and lecithin
CN118021718B (zh) * 2024-04-12 2024-07-02 成都瑞尔医药科技有限公司 一种盐酸普罗帕酮注射液及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600708A (en) 1985-07-19 1986-07-15 American Home Products Corporation Propranolol hydrochloride liquid formulations
HU209251B (en) * 1992-03-13 1994-04-28 Synepos Ag Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
EP0732064B1 (en) 1995-03-15 2001-06-06 Kao Corporation Use of a bitterness relieving agent
JPH1025253A (ja) * 1996-07-12 1998-01-27 Kao Corp 苦味低減化剤及び苦味低減化法
JPH11349492A (ja) * 1998-06-03 1999-12-21 Yamanouchi Pharmaceut Co Ltd 苦味を低減した経口用医薬組成物および苦味低減化方法
JP2001342151A (ja) * 2000-03-31 2001-12-11 Eisai Co Ltd 甘味を有する薬剤組成物
NZ529173A (en) * 2001-05-25 2005-07-29 Warner Lambert Co Stable liquid pharmaceutical composition comprising a GABA analog i.e. gabapentin or pregabalin, and a polyhydric alcohol e.g. glycerol, xylitol, sorbitol, mannitol
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
WO2006093493A1 (en) * 2005-02-25 2006-09-08 Biomarin Pharmaceutical Inc. Room temperature stable aqueous liquid pharmaceutical composition
EP1888030A1 (en) * 2005-05-25 2008-02-20 Janssen Pharmaceutica N.V. Pediatric formulation of topiramate
DE102006020604A1 (de) * 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung
EP2050441A1 (en) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
SI2268282T1 (sl) * 2008-04-25 2015-01-30 Apotex Technologies Inc. Tekoča farmacevtska oblika deferiprona s prijetnim okusom
EP2246044A1 (en) 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker

Also Published As

Publication number Publication date
AR117621A2 (es) 2021-08-18
BRPI1015447A8 (pt) 2017-10-03
MX337463B (es) 2016-03-07
RS55862B2 (sr) 2022-12-30
HRP20181408T4 (hr) 2022-03-04
HUE039937T2 (hu) 2019-02-28
RS57668B2 (sr) 2022-03-31
ES2623936T3 (es) 2017-07-12
PL2421504T5 (pl) 2023-01-02
RU2011139233A (ru) 2013-05-27
EP2497461B1 (en) 2018-06-20
SI2421504T1 (sl) 2017-06-30
SI2497461T1 (sl) 2018-10-30
UA107570C2 (xx) 2015-01-26
KR101713866B1 (ko) 2017-03-09
CY1119390T1 (el) 2018-02-14
LT2497461T (lt) 2018-10-10
PT2421504T (pt) 2017-06-16
CY1120667T1 (el) 2019-12-11
GEP20146087B (en) 2014-05-13
US20150087719A1 (en) 2015-03-26
EP2497461B2 (en) 2021-12-15
CA2755175C (en) 2018-01-02
CO6410278A2 (es) 2012-03-30
CA2755175A1 (en) 2010-10-28
SG172960A1 (en) 2011-08-29
JP2012524773A (ja) 2012-10-18
MA33003B1 (fr) 2012-01-02
PL2497461T3 (pl) 2018-12-31
HRP20170610T4 (hr) 2022-12-09
TW201039862A (en) 2010-11-16
US20120035270A1 (en) 2012-02-09
RS57668B1 (sr) 2018-11-30
IL214674A0 (en) 2011-09-27
ES2685178T3 (es) 2018-10-05
DK2421504T4 (da) 2022-11-14
BRPI1015447A2 (pt) 2016-04-19
WO2010122442A1 (en) 2010-10-28
EP2421504A1 (en) 2012-02-29
TN2011000350A1 (en) 2013-03-27
PL2497461T5 (pl) 2022-06-27
NZ594592A (en) 2013-11-29
PT2497461T (pt) 2018-10-23
KR20120015305A (ko) 2012-02-21
HUE034581T2 (en) 2018-02-28
BRPI1015447B1 (pt) 2020-01-28
AU2010240551B2 (en) 2015-07-16
SI2497461T2 (sl) 2022-04-29
RS55862B1 (sr) 2017-08-31
CL2011002634A1 (es) 2012-06-08
HRP20181408T1 (hr) 2018-11-02
LT2421504T (lt) 2017-06-12
EP2421504B1 (en) 2017-03-08
DK2421504T3 (en) 2017-05-01
AR076338A1 (es) 2011-06-01
DK2497461T3 (en) 2018-09-03
IL214674A (en) 2017-01-31
EP2421504B2 (en) 2022-08-10
EP3384899A1 (en) 2018-10-10
ES2685178T5 (es) 2022-04-13
PL2421504T3 (pl) 2017-08-31
TWI429459B (zh) 2014-03-11
EP2497461A2 (en) 2012-09-12
EP2246044A1 (en) 2010-11-03
ES2623936T5 (es) 2022-11-28
MX2011010766A (es) 2011-10-21
CN102405041A (zh) 2012-04-04
JP5695029B2 (ja) 2015-04-01
EP2497461A3 (en) 2014-01-01
DK2497461T4 (da) 2022-02-14
AU2010240551A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
HRP20170610T1 (hr) Pedijatrijske otopine koje sadrže propranolol
EP2563332B1 (en) Clay compositions
EA025640B1 (ru) Водная композиция, содержащая бромгексин
KR20110067103A (ko) 파라세타몰을 포함하는 액체 약학적 제제
US9056055B2 (en) Flavoured clay-based therapeutic composition
HRP20211247T1 (hr) Pastila
ES2330419T3 (es) Formulaciones de jarabe de ribavirina.
JP3805646B2 (ja) 医薬液剤
US20050032905A1 (en) Oral liquid tolterodine composition
JP4990515B2 (ja) 味質の改善されたイソソルビド製剤
US20190021382A1 (en) Long-lasting sweetener formulations
JP2015537019A5 (hr)
JP6794758B2 (ja) 経口液体医薬組成物
EP2808010A1 (en) Syrup Formulation of Salbutamol
JP4940523B2 (ja) ニザチジンの苦味をマスキングした液剤
CN111467305A (zh) 呋塞米口服溶液及其制备方法
JP2024519421A (ja) カルバメート化合物を含む経口用水性懸濁液製剤
US20120220630A1 (en) Prucalopride oral solution
JP2003055194A (ja) 内服用液剤
JP2020005639A (ja) 果汁感増強剤、及びそれを含有する果汁含有組成物